Total Payments
$539,884
2024 Payments
$45,799
Companies
60
Transactions
1,476
Medicare Patients
7,885
Medicare Billing
$3.0M
Payment Breakdown by Category
Other$303,425 (56.2%)
Consulting$143,049 (26.5%)
Travel$65,604 (12.2%)
Food & Beverage$24,482 (4.5%)
Education$2,055 (0.4%)
Research$1,270 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $299,059 | 121 | 55.4% |
| Consulting Fee | $143,049 | 64 | 26.5% |
| Travel and Lodging | $65,604 | 171 | 12.2% |
| Food and Beverage | $24,482 | 1,087 | 4.5% |
| Honoraria | $4,366 | 3 | 0.8% |
| Education | $2,055 | 28 | 0.4% |
| Unspecified | $1,270 | 2 | 0.2% |
Payments by Type
General
$538,614
1,474 transactions
Research
$1,270
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $83,063 | 110 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $82,240 | 164 | $0 (2024) |
| Exelixis Inc. | $62,411 | 95 | $0 (2024) |
| Eisai Inc. | $47,855 | 111 | $0 (2024) |
| Merck Sharp & Dohme LLC | $46,913 | 80 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $45,997 | 94 | $0 (2024) |
| EMD Serono, Inc. | $31,728 | 43 | $0 (2024) |
| PFIZER INC. | $30,522 | 154 | $0 (2024) |
| Astellas Pharma US Inc | $27,653 | 139 | $0 (2024) |
| Genentech USA, Inc. | $21,328 | 34 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,799 | 164 | Astellas Pharma US Inc ($14,795) |
| 2023 | $26,315 | 181 | PFIZER INC. ($8,220) |
| 2022 | $36,455 | 155 | EISAI INC. ($8,973) |
| 2021 | $38,722 | 116 | Eisai Inc. ($12,794) |
| 2020 | $31,217 | 85 | Bayer HealthCare Pharmaceuticals Inc. ($15,572) |
| 2019 | $15,042 | 123 | EISAI INC. ($6,137) |
| 2018 | $36,295 | 169 | EMD Serono, Inc. ($9,111) |
| 2017 | $310,040 | 483 | AstraZeneca Pharmaceuticals LP ($76,336) |
All Payment Transactions
1,476 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $6.74 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Oncology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.06 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| Category: HORMONE THERAPY | ||||||
| 11/22/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Oncology | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: Oncology | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.74 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $3.62 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 11/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $79.20 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $35.72 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $6.96 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.59 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,358 | 7,971 | $1.6M | $449,474 |
| 2022 | 12 | 2,084 | 10,652 | $1.9M | $573,954 |
| 2021 | 18 | 2,390 | 20,781 | $2.7M | $958,525 |
| 2020 | 12 | 2,053 | 15,403 | $2.5M | $1.0M |
Total Patients
7,885
Total Services
54,807
Medicare Billing
$3.0M
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 260 | 952 | $286,202 | $142,314 | 49.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 559 | 1,205 | $289,003 | $121,040 | 41.9% |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 2023 | 25 | 924 | $725,088 | $99,486 | 13.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 135 | 373 | $57,626 | $24,795 | 43.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 31 | 3,930 | $145,450 | $23,331 | 16.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 113 | 113 | $51,581 | $19,597 | 38.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 95 | 109 | $46,114 | $15,158 | 32.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 64 | 224 | $16,108 | $2,722 | 16.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 59 | 113 | $3,725 | $853.47 | 22.9% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 17 | 28 | $884.00 | $177.52 | 20.1% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2022 | 35 | 1,458 | $916,326 | $179,164 | 19.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 268 | 1,080 | $324,000 | $163,757 | 50.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 603 | 1,304 | $326,000 | $133,156 | 40.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 26 | 3,630 | $72,600 | $22,177 | 30.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 101 | 101 | $49,490 | $18,115 | 36.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 668 | 2,279 | $68,370 | $17,173 | 25.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 116 | 259 | $38,850 | $15,728 | 40.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 76 | 86 | $36,980 | $14,379 | 38.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 12 | 38 | $15,200 | $4,705 | 31.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 72 | 255 | $12,750 | $3,095 | 24.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $4,200 | $1,566 | 37.3% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 93 | 148 | $4,440 | $939.48 | 21.2% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2021 | 50 | 146 | $1.1M | $322,820 | 29.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 309 | 1,393 | $417,900 | $217,894 | 52.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 648 | 1,612 | $403,000 | $171,648 | 42.6% |
About Dr. Robert Alter, MD
Dr. Robert Alter, MD is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306805460.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Alter, MD has received a total of $539,884 in payments from pharmaceutical and medical device companies, with $45,799 received in 2024. These payments were reported across 1,476 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($299,059).
As a Medicare-enrolled provider, Alter has provided services to 7,885 Medicare beneficiaries, totaling 54,807 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 03/18/2006
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1306805460
Products in Payments
- OPDIVO (Biological) $80,706
- IMFINZI (Drug) $77,386
- Lenvima (Drug) $47,855
- Cabometyx (Drug) $46,383
- KEYTRUDA (Biological) $42,691
- Nubeqa (Drug) $29,154
- TECENTRIQ (Biological) $20,861
- Padcev (Drug) $15,925
- Xofigo (Drug) $15,903
- CABOMETYX (Drug) $14,778
- Bavencio (Biological) $9,698
- Xtandi (Drug) $7,809
- SUTENT (Drug) $7,536
- ERLEADA (Drug) $7,484
- Trodelvy (Drug) $7,077
- TALZENNA (Drug) $7,001
- Erleada (Drug) $6,475
- ERBITUX (Drug) $6,442
- LYNPARZA (Drug) $5,657
- Bavencio (Drug) $5,610
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. James Mccloskey, M.d, M.D
Hematology — Payments: $2.8M
Hematology $2.8M
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. David Vesole, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
Dr. Lori Leslie, M.d, M.D
Hematology — Payments: $669,511
Hematology $669,511
Dr. David Siegel, Md, MD
Hematology — Payments: $469,559
Hematology $469,559